Gritstone bio Inc.

Representation of Gritstone bio, a publicly held company previously listed on NASDAQ, as bankruptcy counsel in its chapter 11 case in the District of Delaware. Gritstone bio is a clinical-stage biotechnology company, focused on developing next-generation vaccines aimed at treating cancers as welll as treating and preventing infectious diseases by leveraging its proprietary technology platforms. With the firm’s assistance, the debtor is exploring strategic and transactional alternatives to maximize value for all stakeholders.